Pharmaceuticals News and Research

RSS

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

Sleep disorders are a large area. We are focused on one particular type of sleep disturbance called “non-restorative” sleep. People with this problem do sleep, but they don’t wake up feeling refreshed or feeling that their sleep has had the restorative effects of healthy sleep.

29 Aug 2012

New method simplifies pharmaceutical production of proteins

Engineering researchers at the University of Arkansas have developed a method to simplify the pharmaceutical production of proteins used in drugs that treat a variety of diseases and health conditions, including diabetes, cancer, arthritis and macular degeneration.

29 Aug 2012

Voters need more information on free trade agreement that could impact drug prices

In an opinion piece in the Guardian's "Comment is Free" blog, Dean Baker, co-director of the Center for Economic and Policy Research, discusses potential policies contained within the "Trans-Pacific Partnership Agreement (TPP), a pact that the United States is negotiating with Australia, Canada, Japan and eight other countries in the Pacific region."

29 Aug 2012

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it is developing CLR1502 (GLOW2), a preclinical cancer-targeted optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

29 Aug 2012

Esperance completes EP 100 and paclitaxel Phase 2 combination trial on advanced ovarian cancer

Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi‐center trial of EP‑100 in combination with paclitaxel for patients with advanced ovarian cancer. EP‐100 is a targeted membrane‐disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

29 Aug 2012

MMV390048 shows potent activity against multiple points in malaria parasite's lifecycle

A recently discovered compound from the aminopyridine class not only has the potential to become part of a single-dose cure for all strains of malaria, but might also be able to block transmission of the parasite from person to person, according to a research collaboration involving the Medicines for Malaria Venture (MMV), based in Switzerland, and the Drug Discovery and Development Centre (H3-D) at the University of Cape Town, South Africa.

29 Aug 2012

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced top-line results from a Phase II clinical study of Archexin, its clinical-stage oncology drug candidate.

29 Aug 2012

Elixir Medical’s DESyne BD Novolimus Eluting Coronary Stent System receives CE Mark approval

Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark approval for its DESyne BD Novolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

29 Aug 2012

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

28 Aug 2012

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

Scientists, clinicians and patients will gather at the University of South Florida's Center for Advanced Medical Learning and Simulation (CAMLS) in downtown Tampa Sept. 6 to share research insights and energize the search for a cure for Friedreich's ataxia and related disorders.

28 Aug 2012

Community-based pharmacists could provide added resource in identifying knee OA

Canadian researchers have determined that community-based pharmacists could provide an added resource in identifying knee osteoarthritis (OA). The study, published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), represents the first evidence supporting a collaborative approach to managing knee OA.

28 Aug 2012

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Depomed, Inc. today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug delivery technology.

28 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

BioTime amends license agreement with University of Utah for HyStem technology

BioTime, Inc. announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products covered by the core patents underlying HyStem technology.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Healthy foods consumed more often by the wealthy than poor

Healthy foods such as fruits and vegetables, proteins and non-saturated fats are consumed more often by the wealthy while poorer people consume more carbohydrates, concludes a new study involving people from 17 countries.

27 Aug 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Study explores gender-related differences in patients hospitalized for acute heart failure

Women with acute heart failure have similar in-hospital mortality to men but are less treated in the real world, according to results from the global ALARM-HF registry presented today at the ESC Congress 2012. The findings were presented by Dr John T. Parissis from Greece.

27 Aug 2012

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced that the first patient has been enrolled in an open-label phase III study to investigate the efficacy, safety, and pharmacokinetics of the sustained release triptorelin pamoate 22.5 mg 6-month-formulation in children with central precocious puberty (CPP), a rare disease.

27 Aug 2012

Pharmaceuticals News and Research

Sleep disorder treatment: an interview with Dr Seth Lederman, President and CEO of Tonix Pharmaceuticals

New method simplifies pharmaceutical production of proteins

Voters need more information on free trade agreement that could impact drug prices

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

Esperance completes EP 100 and paclitaxel Phase 2 combination trial on advanced ovarian cancer

MMV390048 shows potent activity against multiple points in malaria parasite's lifecycle

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Elixir Medical’s DESyne BD Novolimus Eluting Coronary Stent System receives CE Mark approval

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

Community-based pharmacists could provide added resource in identifying knee OA

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

BioTime amends license agreement with University of Utah for HyStem technology

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

Healthy foods consumed more often by the wealthy than poor

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Study explores gender-related differences in patients hospitalized for acute heart failure

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence